AstraZeneca has terminated its collaboration with the USA’s MAP Pharmaceuticals which involved the development of a potential asthma treatment for children some four months after the drug failed in a ...

And in an update of clinical trials, AstraZeneca said that the Phase III study of AZD6140, an oral antithrombotic, is in late-stage … AstraZeneca lays out road map for recovery | Fierce Biotech ...

AstraZeneca has suffered another clinical disappointment following the news that a late-stage trial by partner MAP Pharmaceuticals looking at a potential asthma treatment for children has fallen by ...

MAP Pharmaceuticals <MAPP.O> said it plans to suspend development of its experimental paediatric asthma drug, after its licensing partner AstraZeneca <AZN.L> terminated a collaboration on the drug.